Buch, Englisch, 227 Seiten, PB, Format (B × H): 155 mm x 235 mm, Gewicht: 770 g
An Anatomy of Failure, A Blueprint for the Future
Buch, Englisch, 227 Seiten, PB, Format (B × H): 155 mm x 235 mm, Gewicht: 770 g
ISBN: 978-1-4020-8620-5
Verlag: Springer US
After reviewing the history of cancer and its impact on the population, Dr. Faguet exposes the antiquated notions that have driven cancer drug development, documents the stagnation in treatment outcomes despite major advances in cancer genomics and growing NCI budgets, and identifies the multiple factors that sustain the status quo. He shows that, contrary to frequent announcements of breakthroughs, our current cancer control model cannot eradicate most cancers and the reasons why. Significantly, this book also delineates a way forward via a shift from the discredited cell-kill approach of the past to an integrated, evidence-driven cancer control paradigm based on prevention, early diagnosis, and pharmacogenomics. The author's views are based on data published in mainstream scientific journals and other reliable references, 432 of which are cited.
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Humangenetik
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Molekulare Medizin, Zellbiologie
Weitere Infos & Material
Introduction Part I Cancer Statistics: Some Facts
Chapter 1 Assessing the magnitude of the problem
Chapter 2 The problem is growing, not going away Part II What Is Cancer?
Chapter 3 Cancer through the ages
Chapter 4 Our current understanding Part III How Is Cancer Treated?
Chapter 5 The cancer-cell kill paradigm: Hypotheses and corollaries
Chapter 6 Chemotherapy drugs
Chapter 7 Treatment outcomes: Dismal by any standard Part IV Why Does This System Persist?
Chapter 8 The role of the National Cancer Institute
Chapter 9 Publications: The facts and nothing but the facts?
Chapter 10 From the doctors’ perspective
Chapter 11 From the patients’ perspective Part V Where Do We Go From Here?
Chapter 12 A vision for the future
Chapter 13 Shifting from the cell-kill paradigm to molecular therapies
